Abbott (NYSE:ABT) today announced a significant milestone abroad with the opening of a new manufacturing facility in Ireland.

But now, Abbott’s FreeStyle Libre 2 and 3 have received the first and only FDA clearance that allows patients to keep their ...

FreeStyle Libre CGMs, a breakthrough in diabetes care, actually started as a failed product — but key changes made it the ...

Abbott today officially opened its new diabetes technology manufacturing facility in Kilkenny, Ireland. The site will employ ...

Abbott on Nov. 18 held a ceremony to celebrate the official opening of a state-of-the-art manufacturing facility in Kilkenny, ...

Abbott announces $100,000 grant to The Ireland Funds to support the education of young people from three DEIS schools located in Kilkenny ...

The site is a global manufacturing centre of excellence for Abbott’s diabetes care business and will employ more than 800 ...

The new facility is part of a €440m investment made by Abbott in Ireland. The initial announcement was made back in 2022.

Taoiseach Simon Harris and Abbott Chairman and Chief Executive Officer, Robert Ford, at the official opening of the ...

On World Diabetes Day, it's worth taking a look back at the last 10.5 months in the diabetes technology space.

Historically, providers would need to log into separate portals or support different workflows for each CGM manufacturer to review the data from their patients. Additionally, it was cumbersome to ...